| Literature DB >> 35497067 |
Jonas S Sundarakumar1, Albert Stezin1, Abhishek L Menesgere1, Vijayalakshmi Ravindranath1.
Abstract
Background: Despite the growing evidence of metabolic syndrome as a major risk factor for cardiovascular and cerebrovascular disease, there are limited studies from India on its prevalence, especially in the aging population. We aimed to estimate the prevalence of metabolic syndrome and associated comorbidities in two prospective, aging cohorts from rural and urban India.Entities:
Keywords: Aging; Cohort; Gender difference; India; Metabolic syndrome; Prevalence; Rural; Urban
Year: 2022 PMID: 35497067 PMCID: PMC9044001 DOI: 10.1016/j.eclinm.2022.101395
Source DB: PubMed Journal: EClinicalMedicine ISSN: 2589-5370
Criteria used for diagnosis of metabolic syndrome.
| Consensus criteria | NCEP-ATP III criteria |
|---|---|
| 3 or more of the below 5 criteria | |
| Fasting glucose ≥ 100 mg/dl or on drug treatment for diabetes | |
| Systolic BP ≥ 130 mmHg and/or diastolic BP ≥ 85 mmHg or on drug treatment for hypertension | |
| Triglycerides ≥ 150 mg/dl or on drug treatment for elevated triglycerides | |
| HDL cholesterol < 40 mg/dl for men and < 50 mg/dl for women or on drug treatment for low HDL | |
| WC of ≥ 90 cm in men or ≥ 80 cm in women | WC of ≥ 102 cm in men or ≥ 88 cm in women |
*NCEP-ATP III – National Cholesterol Education Program–Adult Treatment Panel III; BP – Blood Pressure; HDL – High Density Lipoprotein; WC – Waist Circumference.
Demographic characteristics of subjects in rural and urban cohorts.
| Demographic features | Rural cohort | Urban cohort | p value |
|---|---|---|---|
| Total sample | 2171 | 332 | - |
| Age | 58.5 ± 10.16 | 66.6 ± 9.55 | 0.0001* |
| Years of education | 3.90 ± 4.6 | 16.6 ± 7.04 | 0.0001* |
| Gender distribution | |||
| Males | 1031 (47.4%) | 191 (57.5%) | 0.0006$ |
| Females | 1140 (52.5%) | 141 (42.4%) | |
| Literates | |||
| Literate | 1185 (54.5%) | 332 (100%) | 0.0001$ |
| Illiterate | 986 (45.5%) | 0 | |
| Religion | |||
| Hindu | 1689 (77.7%) | 207 (62.3%) | – |
| Others | 482 (22.2%) | 125 (37.6%) | |
| Alcohol | |||
| Never used | 1830 (84.2%) | 270 (81.3%) | – |
| Currently using | 124 (5.7%) | 21 (6.3%) | |
| Currently abstinent | 94 (4.3%) | 5 (1.5%) | |
| No response | 123 (5.6%) | 36 (10.8%) | |
| Smoking | |||
| Currently using | 600 (27.6%) | 7 (2.1%) | – |
| Currently abstinent | 339 (15.6%) | 1 (0.3%) | |
| Never used | 1200 (55.2%) | 285 (85.8%) | |
| No response | 32 (1.4%) | 36 (10.8%) | |
| Marital status | |||
| Married/Cohabiting | 1713 (78.9%) | 238 (71.6%) | – |
| Divorced/Separated/Widowed | 378 (17.4%) | 90 (27.1%) | |
| Never married | 10 (0.4%) | 4 (1.2%) | |
| No response | 70 (3.2%) | 0 | |
| Language | |||
| Monolingual | 471 (21.6%) | 15 (4.5%) | – |
| Bilingual | 1178 (54.2%) | 250 (75.3%) | |
| Multilingual | 522 (24.2%) | 67 (20.1%) | |
| Yearly income | |||
| ≤ 100,000 rupees | 809 (37.3%) | 19 (5.7%) | – |
| > 100,000 rupees | 1362 (62.7%) | 313 (94.2%) | |
| Occupation | |||
| Agriculture | 1155 (53.2%) | 10 (3.0%) | – |
| Never worked/retired | 550 (25.3%) | 80 (24.0%) | |
| Manual laborer | 349 (16.0%) | 2 (0.6%) | |
| Professional | 52 (2.3%) | 151 (45.4%) | |
| Business | 26 (1.1%) | 82 (24.6%) | |
| Skilled jobs | 21 (0.9%) | 4 (1.2%) | |
| Semi-skilled labor | 18 (0.8%) | 3 (0.9%) |
The significant p-values (corrected p < 0.002) are represented by * for independent t-test and by $ for Chi-square test after correcting for multiple comparisons.
Prevalence of individual parameters of metabolic syndrome in rural and urban cohorts based on the consensus criteria and NCEP-ATP III criteria.
| Rural cohort | Urban cohort | p value | |
|---|---|---|---|
| Number of subjects | 2171 | 332 | - |
| Elevated fasting glucose | 1116 (51.3%) | 168 (50.6%) | NS |
| or diagnosis / drug treatment | |||
| Elevated blood pressure | 865 (39.8%) | 220 (66.2%) | 0.0001 |
| or diagnosis / drug treatment | |||
| Elevated triglycerides | 982 (45.1%) | 73 (21.9%) | 0.0001 |
| or diagnosis / drug treatment | |||
| Low HDL | 982 (45.1%) | 86 (25.9%) | 0.0001 |
| or diagnosis / drug treatment | |||
| Higher waist circumference | 833 (38.3%) | 202 (60.9%) | 0.0001 |
| (Consensus criteria | |||
| Higher waist circumference | 362 (16.6%) | 127 (38.2%) | 0.0001 |
| (NCEP ATP-III criteria | |||
| Metabolic syndrome | 1004 (46.2%) | 182 (54.8%) | 0.002 |
| (Consensus criteria) | |||
| Metabolic syndrome | |||
| (NCEP ATP-III criteria) | 877 (40.3%) | 150 (45.1%) | NS |
The statistically significant p-values (corrected p<0.002) are represented by $.
for Chi-square test after correcting for multiple comparisons.
≥100 mg/dl.
≥130 mm Hg systolic and/or ≥ 85 mm Hg diastolic.
≥150 mg/dl.
<40 mg/dl in men; < 50 mg/dl in women.
≥90 cm in men; ≥ 80 cm in women.
≥102 cm in men; ≥88 cm in women.
Figure 1Gender-wise prevalence of metabolic syndrome (%).
Estimated according to the consensus criteria, among aging rural and urban Indians belonging to Srinivaspura Aging, Neuro Senescence and COGnition (SANSCOG) cohort and Tata Longitudinal Study on Aging (TLSA) cohorts. Male participants, female participants and overall participants are represented by blue-, green-, and black-colored bars, respectively). ⁎⁎⁎ Represents significant p value <0.002; NS – Not Significant.
Figure 2Age-stratified prevalence of metabolic syndrome (%).
Estimated according to the consensus criteria, among aging rural Indians (represented by blue-colored bars) and urban Indians (represented by green-colored bars) belonging to Srinivaspura Aging, Neuro Senescence and COGnition (SANSCOG) cohort and Tata Longitudinal Study on Aging (TLSA) cohorts, respectively. The age groups were categorized as 45–54 years, 55–64 years, 65–74 years and ≥ 75 years, represented by blue-, green-, red-, and black-colored bars, respectively). ⁎⁎⁎Represents significant p value <0.002; NS – Not Significant.
Prevalence of co-morbidities in rural and urban populations.
| Clinical comorbidities | Rural cohort | Urban cohort | p value | ||||
|---|---|---|---|---|---|---|---|
| Overall (%) | Diagnosed (%) | Undiagnosed (%) | Overall (%) | Diagnosed (%) | Undiagnosed (%) | ||
| Dyslipidemia | 1748 (80.5%) | 16 (0.9%) | 1732 (99.1%) | 283 (85.2%) | 80 (28.2%) | 203 (71.7%) | 0.002 |
| Hypertension | 564 (25.9%) | 162 (28.7%) | 402 (71.3%) | 260 (78.3%) | 140 (53.8%) | 120 (46.2%) | 0.0001 |
| Type 2 diabetes mellitus | 559 (25.7%) | 207 (37.0%) | 352 (62.9%) | 165 (49.6%) | 107 (64.8%) | 58 (35.1%) | 0.0001 |
| Cardiovascular disease | 29 (1.3%) | 29 (100%) | NA | 59 (17.7%) | 59 (100%) | NA | 0.0001 |
| Cerebrovascular disease | 16 (0.7%) | 16 (100%) | NA | 12 (3.3%) | 12 (100%) | NA | 0.0001 |
| Cancer | 8 (0.3%) | 8 (100%) | NA | 10 (3%) | 10 (100%) | NA | 0.0001 |
The statistically significant p-values (< 0.002) are represented by $.
for Chi-square test after correcting for multiple comparisons. NA: Not applicable (screening tests not performed).
Dyslipidemia: Self-reported diagnosis / drug treatment and/or any one of total cholesterol ≥ 200 mg/dl or triglycerides ≥ 150 mg/dl or HDL in men < 40 mg/dl or women < 50 mg/dl or LDL ≥ 100 mg/dl.
Hypertension: Self-reported diagnosis / drug treatment and/or BP ≥ 140 / 90 mm Hg.
Type 2 diabetes mellitus: Self-reported diagnosis / drug treatment and/or fasting glucose ≥ 126 mg/dl and/or HbA1c ≥ 6.5.
Cardiovascular disease: Self-reported diagnosis.
Cerebrovascular disease: Self-reported diagnosis.
Cancer: Self-reported diagnosis.